Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts

Bong Joo Park, Jong Chul Park, Hideaki Taguchi, Kazutaka Fukushima, Suong Hyu Hyon, Kosuke Takatori

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

This is the first report to investigate the antifungal susceptibility of 21 clinical isolates of seven Candida species to epigallocatechin 3-O-gallate (EGCg) and to compare with six antifungal agents, amphotericin B (AMPH), fluconazole (FLCZ), flucytosin (5FC), itraconazole (ITCZ), micafungin (MCFG), and miconazole (MCZ), using a method following the National Committee for Clinical Laboratory Standards (NCCLS) M27-A guidelines. Among the tested species, Candida glabrata exhibited the highest susceptibility to EGCg (MIC50, 0.5-1 μg/ml and MIC90, 1-2 μg/ml) compared favorably with FLCZ, although they were slightly less susceptible than to AMPH, 5FC, MCFG, ITCZ, and MCZ. Candida guilliemondii and Candida parapsilosis (MIC50, 1-4 μg/ml and MIC90, 2-16 μg/ml) were also susceptible to EGCg, although they appear to be slightly less susceptible to EGCg than C. glabrata and the other antifungal agents tested. Moreover, the susceptibility of Candida krusei strains (MIC50, 2 μg/ml and MIC90, 4-8 μg/ml) to EGCg was approximately 2- to 8-fold higher than those of 5FC and FLCZ. Our data indicate that EGCg can inhibit clinically pathogenic Candida species, although the concentrations of EGCg for antifungal susceptibility were slightly higher than those of tested antifungal agents on the whole. Based on these results, we suggest that EGCg may be effectively used as a possible agent or adjuvant for antifungal therapy in Candidiasis.

Original languageEnglish
Pages (from-to)401-405
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume347
Issue number2
DOIs
Publication statusPublished - 2006 Aug 25

Fingerprint

Yeast
Candida
Yeasts
Fluconazole
Antifungal Agents
Miconazole
Candida glabrata
Itraconazole
Amphotericin B
Clinical laboratories
epigallocatechin gallate
Candidiasis
Guidelines

All Science Journal Classification (ASJC) codes

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

Park, Bong Joo ; Park, Jong Chul ; Taguchi, Hideaki ; Fukushima, Kazutaka ; Hyon, Suong Hyu ; Takatori, Kosuke. / Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts. In: Biochemical and Biophysical Research Communications. 2006 ; Vol. 347, No. 2. pp. 401-405.
@article{a710197077974a23bc3e59be2612d2f4,
title = "Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts",
abstract = "This is the first report to investigate the antifungal susceptibility of 21 clinical isolates of seven Candida species to epigallocatechin 3-O-gallate (EGCg) and to compare with six antifungal agents, amphotericin B (AMPH), fluconazole (FLCZ), flucytosin (5FC), itraconazole (ITCZ), micafungin (MCFG), and miconazole (MCZ), using a method following the National Committee for Clinical Laboratory Standards (NCCLS) M27-A guidelines. Among the tested species, Candida glabrata exhibited the highest susceptibility to EGCg (MIC50, 0.5-1 μg/ml and MIC90, 1-2 μg/ml) compared favorably with FLCZ, although they were slightly less susceptible than to AMPH, 5FC, MCFG, ITCZ, and MCZ. Candida guilliemondii and Candida parapsilosis (MIC50, 1-4 μg/ml and MIC90, 2-16 μg/ml) were also susceptible to EGCg, although they appear to be slightly less susceptible to EGCg than C. glabrata and the other antifungal agents tested. Moreover, the susceptibility of Candida krusei strains (MIC50, 2 μg/ml and MIC90, 4-8 μg/ml) to EGCg was approximately 2- to 8-fold higher than those of 5FC and FLCZ. Our data indicate that EGCg can inhibit clinically pathogenic Candida species, although the concentrations of EGCg for antifungal susceptibility were slightly higher than those of tested antifungal agents on the whole. Based on these results, we suggest that EGCg may be effectively used as a possible agent or adjuvant for antifungal therapy in Candidiasis.",
author = "Park, {Bong Joo} and Park, {Jong Chul} and Hideaki Taguchi and Kazutaka Fukushima and Hyon, {Suong Hyu} and Kosuke Takatori",
year = "2006",
month = "8",
day = "25",
doi = "10.1016/j.bbrc.2006.06.037",
language = "English",
volume = "347",
pages = "401--405",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "2",

}

Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts. / Park, Bong Joo; Park, Jong Chul; Taguchi, Hideaki; Fukushima, Kazutaka; Hyon, Suong Hyu; Takatori, Kosuke.

In: Biochemical and Biophysical Research Communications, Vol. 347, No. 2, 25.08.2006, p. 401-405.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antifungal susceptibility of epigallocatechin 3-O-gallate (EGCg) on clinical isolates of pathogenic yeasts

AU - Park, Bong Joo

AU - Park, Jong Chul

AU - Taguchi, Hideaki

AU - Fukushima, Kazutaka

AU - Hyon, Suong Hyu

AU - Takatori, Kosuke

PY - 2006/8/25

Y1 - 2006/8/25

N2 - This is the first report to investigate the antifungal susceptibility of 21 clinical isolates of seven Candida species to epigallocatechin 3-O-gallate (EGCg) and to compare with six antifungal agents, amphotericin B (AMPH), fluconazole (FLCZ), flucytosin (5FC), itraconazole (ITCZ), micafungin (MCFG), and miconazole (MCZ), using a method following the National Committee for Clinical Laboratory Standards (NCCLS) M27-A guidelines. Among the tested species, Candida glabrata exhibited the highest susceptibility to EGCg (MIC50, 0.5-1 μg/ml and MIC90, 1-2 μg/ml) compared favorably with FLCZ, although they were slightly less susceptible than to AMPH, 5FC, MCFG, ITCZ, and MCZ. Candida guilliemondii and Candida parapsilosis (MIC50, 1-4 μg/ml and MIC90, 2-16 μg/ml) were also susceptible to EGCg, although they appear to be slightly less susceptible to EGCg than C. glabrata and the other antifungal agents tested. Moreover, the susceptibility of Candida krusei strains (MIC50, 2 μg/ml and MIC90, 4-8 μg/ml) to EGCg was approximately 2- to 8-fold higher than those of 5FC and FLCZ. Our data indicate that EGCg can inhibit clinically pathogenic Candida species, although the concentrations of EGCg for antifungal susceptibility were slightly higher than those of tested antifungal agents on the whole. Based on these results, we suggest that EGCg may be effectively used as a possible agent or adjuvant for antifungal therapy in Candidiasis.

AB - This is the first report to investigate the antifungal susceptibility of 21 clinical isolates of seven Candida species to epigallocatechin 3-O-gallate (EGCg) and to compare with six antifungal agents, amphotericin B (AMPH), fluconazole (FLCZ), flucytosin (5FC), itraconazole (ITCZ), micafungin (MCFG), and miconazole (MCZ), using a method following the National Committee for Clinical Laboratory Standards (NCCLS) M27-A guidelines. Among the tested species, Candida glabrata exhibited the highest susceptibility to EGCg (MIC50, 0.5-1 μg/ml and MIC90, 1-2 μg/ml) compared favorably with FLCZ, although they were slightly less susceptible than to AMPH, 5FC, MCFG, ITCZ, and MCZ. Candida guilliemondii and Candida parapsilosis (MIC50, 1-4 μg/ml and MIC90, 2-16 μg/ml) were also susceptible to EGCg, although they appear to be slightly less susceptible to EGCg than C. glabrata and the other antifungal agents tested. Moreover, the susceptibility of Candida krusei strains (MIC50, 2 μg/ml and MIC90, 4-8 μg/ml) to EGCg was approximately 2- to 8-fold higher than those of 5FC and FLCZ. Our data indicate that EGCg can inhibit clinically pathogenic Candida species, although the concentrations of EGCg for antifungal susceptibility were slightly higher than those of tested antifungal agents on the whole. Based on these results, we suggest that EGCg may be effectively used as a possible agent or adjuvant for antifungal therapy in Candidiasis.

UR - http://www.scopus.com/inward/record.url?scp=33745909158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745909158&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2006.06.037

DO - 10.1016/j.bbrc.2006.06.037

M3 - Article

C2 - 16831406

AN - SCOPUS:33745909158

VL - 347

SP - 401

EP - 405

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 2

ER -